Journal article

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Chee Khoon Lee, David Goldstein, Emma Gibbs, Heikki Joensuu, John Zalcberg, Jaap Verweij, Paolo G Casali, Robert G Maki, Angela Cioffi, Grant Mcarthur, Sarah J Lord, Desmond Yip, Yada Kanjanapan, Piotr Rutkowski

EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2015

Abstract

PURPOSE: Metastatic gastrointestinal stromal tumour (GIST) is generally an incurable disease with variable response to imatinib. We aimed to develop prognostic nomograms to predict overall survival (OS) and progression-free survival (PFS) for patients treated with imatinib. METHODS: Nomograms were developed in a training cohort (n=330) of patients treated in a randomised trial (EORTC-ISG-AGITG 62005 phase III study) using Cox regression models, and validated in patients (n=236) treated in routine clinical care from six referral centres. Nomogram performance was assessed by calculating the c statistic. A classification based on the nomograms' scores was generated to group patients according t..

View full abstract

University of Melbourne Researchers